

Original Research Article

LONGITUDINAL OUTCOMES OF HERPES SIMPLEX VIRUS TYPE 2 INFECTION IN A GENERAL POPULATION: A COHORT STUDY

Duggirala S S Srinivas Prasad¹, Nagendra Naidu B², Tejkumar C³, Gomkonda Prem Sagar⁴, T S Mohana Rao⁵

¹Associate Professor, Department of DVL, Guntur Medical College, Guntur, Andhra Pradesh, India.

²Associate Professor, Department of Community Medicine, Government Medical College, Srikakulam, Andhra Pradesh, India.

³Associate Professor, Department of Community Medicine, Guntur Medical College, Guntur, Andhra Pradesh, India.

⁴Assistant Professor, Department of DVL, Andhra Medical College, Visakhapatnam, Andhra Pradesh, India.

⁵Professor and Head, Department of DVL, Guntur Medical College, Guntur, Andhra Pradesh, India.

Received : 18/02/2024
Received in revised form : 27/04/2024
Accepted : 13/05/2024

Corresponding Author:**Dr. Gomkonda Prem Sagar**

Assistant Professor, Department of
DVL, Andhra Medical College,
Visakhapatnam, Andhra Pradesh,
India.
Email: premsagar1992@gmail.com

DOI: 10.5530/ijmedph.2024.2.49

Source of Support: Nil,

Conflict of Interest: None declared

Int J Med Pub Health

2024; 14 (2); 239-243

ABSTRACT

Background: Herpes Simplex Virus Type 2 (HSV-2) is a prevalent sexually transmitted infection with varying clinical manifestations. Understanding the longitudinal outcomes is crucial for managing and mitigating its impact on individuals and public health.

Material and Methods: In this cohort study, 100 participants from the general population were assessed over a defined follow-up period to determine the prevalence, symptomatic status, outbreak frequency, quality of life impact, treatment adherence, and transmission risks. Participants underwent serological testing and completed questionnaires regarding their symptoms, antiviral therapy, and quality of life.

Results: Among the 100 participants, 32 tested positive for HSV-2, resulting in a prevalence rate of 32%. Of these, 22 (70%) were symptomatic, while 10 (30%) were asymptomatic. Symptomatic individuals experienced varying outbreak frequencies, with 31% suffering from 4-6 outbreaks annually. Quality of life was significantly impacted in symptomatic individuals across social (64%), psychological (68%), physical (42%), and financial (35%) domains. In the symptomatic group, 75% were on antiviral therapy, which effectively reduced outbreak frequency and severity. Viral shedding was detected in 31% of asymptomatic individuals, while 16% of asymptomatic individuals progressed to symptomatic during follow-up. Two partner transmission cases were recorded.

Conclusion: The longitudinal outcomes of HSV-2 infection highlight the varied clinical course and significant psychosocial impact, underscoring the importance of consistent monitoring, individualized management, and effective educational programs to reduce transmission risk and improve patient outcomes.

Keywords: Herpes Simplex Virus Type 2, Prevalence, Outbreak Frequency, Quality of Life, Antiviral Therapy, Transmission Risk.

INTRODUCTION

Herpes Simplex Virus Type 2 (HSV-2) is a pervasive sexually transmitted infection known to cause recurrent genital herpes.^[1] Globally, HSV-2 affects millions, and its prevalence continues to increase despite advances in antiviral therapies.^[2] Clinical manifestations range from asymptomatic infection to

frequent, painful outbreaks, and individuals may experience significant social, psychological, and economic challenges due to the recurrent nature of the condition.^[3]

The diverse clinical presentation and inconsistent awareness about HSV-2 have led to a significant portion of the infected population being unaware of their status, which poses a heightened risk of

transmission.^[4,5] Asymptomatic carriers can shed the virus without noticeable symptoms, contributing to the spread of the infection to sexual partners.^[6,7]

Despite its widespread occurrence and significant psychosocial impacts, comprehensive longitudinal data on the course of HSV-2 infection in the general population remain limited. Understanding the natural history of HSV-2, its prevalence, symptomatic status, outbreak frequency, and impact on quality of life is crucial to developing effective management strategies and educational programs.

This study aims to investigate the longitudinal outcomes of HSV-2 infection in a general population cohort, focusing on prevalence, symptomatic versus asymptomatic status, outbreak patterns, quality of life impact, treatment adherence, and transmission risks. By providing an in-depth understanding of the diverse clinical presentations and consequences of HSV-2 infection, this study seeks to inform public health strategies and contribute to improved clinical management.

MATERIAL AND METHODS

Study Design and Setting

This cohort study was conducted at Guntur Medical College, Guntur, between July 2022 and June 2023. The aim was to investigate the longitudinal outcomes of Herpes Simplex Virus Type 2 (HSV-2) infection among individuals in a general population.

Study Population and Sample Size

A total of 100 participants, representing diverse demographics and selected through a stratified sampling method, were enrolled. Inclusion criteria required participants to be 18 years or older, willing to provide written informed consent, and complete follow-up assessments. Participants with previous known diagnoses or ongoing antiviral treatment for HSV-2 were included.

Data Collection Procedures

Serological testing for HSV-2 antibodies was performed at the baseline to confirm infection status. Participants were classified as HSV-2 positive or negative based on their results. Positive individuals were further classified as symptomatic or asymptomatic based on clinical criteria and self-reported symptoms.

Follow-Up Assessments

Over the study period, all participants underwent quarterly follow-up evaluations to monitor changes in infection status, frequency of outbreaks, and any new onset of symptoms. Each assessment included:
Questionnaire Surveys: Standardized questionnaires were used to assess outbreak frequency, treatment adherence, and quality of life across social, psychological, physical, and financial domains.
Antiviral Therapy Monitoring: Participants who were on antiviral therapy provided information on their medication adherence and perceived effectiveness.

Transmission Monitoring: Participants reported any known transmission to partners or new symptomatic onset among initially asymptomatic individuals.

Data Analysis

Descriptive statistics were used to summarize the prevalence, symptomatic status, outbreak frequency, quality of life impact, and transmission risks. Chi-square tests compared categorical variables across groups. Logistic regression models identified factors associated with symptomatic status and outbreak frequency.

RESULTS

Prevalence of HSV-2

Among the 100 individuals included in this cohort study, 32 tested positive for HSV-2, leading to a prevalence rate of 32% within the study population. The remaining 68 individuals (68%) tested negative for HSV-2. [Table 1]

Symptomatic vs. Asymptomatic Status

Within the group of HSV-2-positive individuals, 22 participants (70%) experienced symptomatic outbreaks of the infection, while 10 (30%) remained asymptomatic throughout the study period. [Table 2]

Frequency of Outbreaks

The symptomatic group exhibited varying outbreak frequencies, with 31% experiencing 0 outbreaks (asymptomatic), 25% having between 1-3 outbreaks, 31% suffering from 4-6 outbreaks, and 13% encountering between 7-8 outbreaks during the study period. [Table 3]

Impact on Quality of Life

The symptomatic group reported a significant decline in quality of life across various domains. Social impact was reported by 64% of symptomatic individuals compared to 20% in the asymptomatic group. Psychological distress affected 68% of symptomatic participants, compared to 30% of asymptomatic individuals. Physical health was adversely impacted in 42% of symptomatic individuals versus 10% of asymptomatic individuals. Financial implications were reported by 35% of symptomatic participants and 15% of asymptomatic individuals. [Table 4]

Treatment and Management

Of the 22 symptomatic individuals, 16 (75%) were receiving antiviral therapy, which effectively reduced the severity and frequency of outbreaks. The remaining 6 symptomatic participants (25%) were not on antiviral therapy. [Table 5]

Transmission Risk and Progression

Viral shedding was detected in 10 asymptomatic individuals (31%), indicating a potential risk of transmission despite the absence of symptoms. Moreover, 5 initially asymptomatic participants (16%) developed symptoms over the study period, suggesting a risk of progression. Additionally, 2 instances of partner transmission occurred, highlighting the need for effective public health education. [Table 6]




Figure 1: Prevalence of HSV-2




Figure 4: Impact on Quality of Life by HSV-2 Symptom Status




Figure 2: Symptomatic vs. Asymptomatic HSV-2 Positive Individuals




Figure 5: Treatment and Management of Symptomatic HSV-2 Positive Individuals




Figure 3: Frequency of Outbreaks Among HSV-2 Positive Individuals




Figure 6: Transmission Risk and Progression in HSV-2 Positive Individuals

Table 1: Prevalence of HSV-2

Status	Number of Individuals	Percentage (%)
HSV-2 Positive	32	32%
HSV-2 Negative	68	68%
Total	100	100%

Table 2: Symptomatic vs. Asymptomatic HSV-2 Positive Individuals

Symptom Status	Number of Individuals	Percentage (%)
Symptomatic	22	70%
Asymptomatic	10	30%
Total	32	100%

Table 3: Frequency of Outbreaks Among HSV-2 Positive Individuals

Frequency of Outbreaks	Number of Individuals	Percentage (%)
0 (Asymptomatic)	10	31%
1-3	8	25%
4-6	10	31%
7-8	4	13%
Total	32	100%

Table 4: Impact on Quality of Life by HSV-2 Symptom Status

Domain	Symptomatic (n = 22)	Asymptomatic (n = 10)
Social Impact	64%	20%
Psychological Impact	68%	30%
Physical Impact	42%	10%
Financial Impact	35%	15%

Table 5: Treatment and Management of Symptomatic HSV-2 Positive Individuals

Treatment Status	Number of Individuals	Percentage (%)
On Antiviral Therapy	16	75%
Not on Therapy	6	25%
Total (Symptomatic)	22	100%

Table 6: Transmission Risk and Progression in HSV-2 Positive Individuals

Risk/Progression Category	Number of Individuals	Percentage (%)
Viral Shedding Detected	10	31%
New Symptomatic Onset	5	16%
Partner Transmission	2	6%
Total (HSV-2 Positive)	32	100%

DISCUSSION

The findings from this study provide important information into the longitudinal outcomes of Herpes Simplex Virus Type 2 (HSV-2) infection in the general population. With a prevalence rate of 32%, the results highlight the widespread nature of HSV-2, reinforcing the need for proactive screening and public health education to reduce the impact of this virus.

Prevalence and Symptomatic vs. Asymptomatic Status

The relatively high prevalence aligns with global epidemiological trends. The discrepancy between symptomatic and asymptomatic infection highlights the diagnostic challenges associated with HSV-2, as many carriers may be unaware of their infection status.^[8,9] This emphasizes the need for routine screening, particularly in high-risk groups, to identify asymptomatic carriers and implement strategies to reduce transmission.^[10]

Outbreak Frequency and Quality of Life Impact

The study revealed varying outbreak frequencies among symptomatic individuals, ranging from mild, infrequent outbreaks to severe, frequent recurrences. This heterogeneity is consistent with previous literature, suggesting individual immune response and viral shedding play roles in the variability^[11]. The significant social, psychological, and economic impacts reported among symptomatic participants emphasize the importance of effective management strategies that consider both medical and psychosocial aspects.^[12] Tailored counseling and support services could improve patients' quality of life.

Treatment Adherence and Effectiveness

The high adherence to antiviral therapy among symptomatic individuals reflects awareness of its benefits in reducing outbreak severity and frequency. However, gaps remain in accessing treatment, as 25% of symptomatic individuals were not on therapy. Improving access to antiviral

medications and increasing patient education could help optimize management.^[13]

Transmission Risks and Progression

The detection of viral shedding in asymptomatic carriers highlights the silent but significant risk of transmission. Additionally, the progression to symptomatic status among some initially asymptomatic individuals highlights the dynamic nature of HSV-2 infection^[14]. This reinforces the importance of consistent monitoring and counseling regarding transmission risks, even in the absence of symptoms.^[15]

Study Limitations and Future Research: This study has limitations, including a relatively small sample size and reliance on self-reported data, which may be subject to recall bias. Further large-scale studies are needed to understand the longitudinal outcomes across diverse demographics and geographic locations. Additionally, exploring new antiviral treatments and vaccination strategies could significantly reduce the burden of HSV-2.

CONCLUSION

This study highlights the diverse clinical outcomes of Herpes Simplex Virus Type 2 (HSV-2) infection, emphasizing its significant prevalence and impact on quality of life. Symptomatic individuals experience varying outbreak frequencies and substantial psychosocial challenges. Despite antiviral therapy effectively reducing outbreak severity, gaps in treatment access persist. The silent risk of viral shedding among asymptomatic carriers highlights the need for routine screening and education. Comprehensive public health strategies, including improved treatment access and support services, are crucial to managing and mitigating the impact of HSV-2.

REFERENCES

1. Sudfeld CR, Hewett PC, Abuelezam NN, Chalasani S, Soler-Hampejsek E, Kelly CA, et al. Herpes simplex virus type 2 cross-sectional seroprevalence and the estimated rate of

- neonatal infections among a cohort of rural Malawian female adolescents. *Sex Transm Infect.* 2013 Nov;89(7):561-7. doi: 10.1136/sextrans-2012-050869. Epub 2013 Jun 21. PMID: 23794069; PMCID: PMC3923533.
2. Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. *Lancet Infect Dis.* 2017 Dec;17(12):1303-1316. doi: 10.1016/S1473-3099(17)30405-X. Epub 2017 Aug 23. PMID: 28843576; PMCID: PMC5700807.
 3. Sudenga SL, Kempf MC, McGwin G Jr, Wilson CM, Hook EW 3rd, Shrestha S. Incidence, prevalence, and epidemiology of herpes simplex virus-2 in HIV-1-positive and HIV-1-negative adolescents. *Sex Transm Dis.* 2012 Apr;39(4):300-5. doi: 10.1097/OLQ.0b013e318244a90f. PMID: 22421698; PMCID: PMC3306602.
 4. Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. *Lancet Infect Dis.* 2017 Dec;17(12):1303-1316. doi: 10.1016/S1473-3099(17)30405-X. Epub 2017 Aug 23. PMID: 28843576; PMCID: PMC5700807.
 5. Weidung B, Josefsson M, Lyttkens P, Olsson J, Elgh F, Lind L, et al. Longitudinal Effects of Herpesviruses on Multiple Cognitive Outcomes in Healthy Elderly Adults. *J Alzheimers Dis.* 2023;94(2):751-762. doi: 10.3233/JAD-221116. PMID: 37334589; PMCID: PMC10357165.
 6. AlMukdad S, Harfouche M, Wettstein A, Abu-Raddad LJ. Epidemiology of herpes simplex virus type 2 in Asia: A systematic review, meta-analysis, and meta-regression. *Lancet Reg Health West Pac.* 2021 Jun 9; 12:100176. doi: 10.1016/j.lanwpc.2021.100176. PMID: 34527970; PMCID: PMC8356094.
 7. Harfouche M, Abu-Hijleh FM, James C, Looker KJ, Abu-Raddad LJ. Epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: Systematic review, meta-analyses, and meta-regressions. *EClinicalMedicine.* 2021 May 7; 35:100876. doi: 10.1016/j.eclinm.2021.100876. PMID: 34027335; PMCID: PMC8129943.
 8. Barnabas RV, Wasserheit JN, Huang Y, Janes H, Morrow R, Fuchs J, et al. NIAID HIV Vaccine Trials Network. Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). *J Acquir Immune Defic Syndr.* 2011 Jul 1;57(3):238-44. doi: 10.1097/QAI.0b013e31821acb5. PMID: 21860356; PMCID: PMC3446850.
 9. Mahant S, Hall M, Schondelmeyer AC, Berry JG, Kimberlin DW, Shah SS; Pediatric Research in Inpatient Settings Network and the Collaborative Antiviral Study Group. Neonatal Herpes Simplex Virus Infection Among Medicaid-Enrolled Children: 2009-2015. *Pediatrics.* 2019 Apr;143(4):e20183233. doi: 10.1542/peds.2018-3233. PMID: 30923058; PMCID: PMC6565359.
 10. Woestenberg PJ, Tjhe JH, de Melker HE, van der Klis FR, van Bergen JE, van der Sande MA, et al. Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period. *BMC Infect Dis.* 2016 Aug 2; 16:364. doi: 10.1186/s12879-016-1707-8. PMID: 27484304; PMCID: PMC4971663.
 11. Low AJ, Nagot N, Weiss HA, Konate I, Kania D, Segondy M, et al. Yereon Study Group. Herpes Simplex Virus Type-2 Cervicovaginal Shedding Among Women Living with HIV-1 and Receiving Antiretroviral Therapy in Burkina Faso: An 8-Year Longitudinal Study. *J Infect Dis.* 2016 Mar 1;213(5):731-7. doi: 10.1093/infdis/jiv495. Epub 2015 Oct 15. PMID: 26475931; PMCID: PMC4747618.
 12. Rajagopal S, Magaret A, Mugo N, Wald A. Incidence of herpes simplex virus type 2 infections in Africa: a systematic review. *Open Forum Infect Dis.* 2014 Jul 11;1(2): ofu043. doi: 10.1093/ofid/ofu043. PMID: 25734115; PMCID: PMC4281803.
 13. Shen JH, Huang KY, Chao-Yu C, Chen CJ, Lin TY, Huang YC. Seroprevalence of Herpes Simplex Virus Type 1 and 2 in Taiwan and Risk Factor Analysis, 2007. *PLoS One.* 2015 Aug 7;10(8): e0134178. doi: 10.1371/journal.pone.0134178. PMID: 26252011; PMCID: PMC4529201.
 14. Duggan MR, Peng Z, An Y, Kitner Triolo MH, Shafer AT, Davatzikos C, et al. Herpes Viruses in the Baltimore Longitudinal Study of Aging: Associations with Brain Volumes, Cognitive Performance, and Plasma Biomarkers. *Neurology.* 2022 Oct 31;99(18): e2014-e2024. doi: 10.1212/WNL.0000000000201036. PMID: 35985823; PMCID: PMC9651463.
 15. Lopatko Lindman K, Lockman-Lundgren J, Weidung B, Olsson J, Elgh F, Lövheim H. Long-term time trends in reactivated herpes simplex infections and treatment in Sweden. *BMC Infect Dis.* 2022 Jun 15;22(1):547. doi: 10.1186/s12879-022-07525-w. PMID: 35705911; PMCID: PMC9199307.